CME
Better Early Than Late: CDK4/6 Inhibition in HR +, HER2- Early Breast Cancer
April 19, 2023
Host: Hope S. Rugo, MD, FASCO Guest: Peter Schmid, FRCP, MD, PhD HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationa
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!